Slava Stamova

Leibniz Association — Germany

Immunology and Microbiology · Life Sciences

18h-index1.2kcitations60works5.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(28), Glioma Diagnosis and Treatment(27), CAR-T cell therapy research(25), Cancer Immunotherapy and Biomarkers(16), Immune Cell Function and Interaction(12)

Publications60 total

IL-2 and TCR stimulation induce expression and secretion of IL-32β by human T cells
Frontiers in Immunology·2024· 6 citedOpen Access
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton
Cancer Cell·2024· 5 citedOpen Access
TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastoma
Acta Neuropathologica Communications·2023· 11 citedOpen Access
Suppl. Figure 2 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Figure 1 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Figure 2 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Table 1, 3-8 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Figure 7 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Figure 4 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Figure 6 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Figure 9 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Figure 5 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Figure 1 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Table 2 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Supplementary Figure Legends from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Figure 10 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Table 2 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Table 1, 3-8 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Suppl. Figure 4 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
Supplementary Figure Legends from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Philipp Beckhove(33), Anchana Rathinasamy(23), Christel Herold‐Mende(22), Steffen Dettling(21), Rolf Warta(21), Carmen Rapp(21), David Reuß(21), Saskia Roesch(21), Christine Jungk(21), Volker Eckstein(21), Niels Grabe(21), Andreas von Deimling(21), Andreas Unterberg(21), Martina Schnölzer(20), Kolja Pocha(20), Uwe Warnken(20), Markus A. Weigand(20), Christoph Schramm(19), Michael Bachmann(17), Marc Cartellieri(16)